120 related articles for article (PubMed ID: 14517486)
41. Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin.
Ichinose A; Mimuro J; Koide T; Aoki N
Thromb Res; 1984 Feb; 33(4):401-7. PubMed ID: 6710439
[TBL] [Abstract][Full Text] [Related]
42. Fibrinolysis and fibrinogenolysis by Val442-plasmin.
Ney KA; Pizzo SV
Biochim Biophys Acta; 1982 Nov; 708(2):218-24. PubMed ID: 6216916
[TBL] [Abstract][Full Text] [Related]
43. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
[TBL] [Abstract][Full Text] [Related]
44. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Idell S
Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
[TBL] [Abstract][Full Text] [Related]
45. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599
[TBL] [Abstract][Full Text] [Related]
46. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
47. Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in vitro.
Van Leer C; Stutz M; Haeberli A; Geiser T
Thromb Haemost; 2005 Dec; 94(6):1257-64. PubMed ID: 16411403
[TBL] [Abstract][Full Text] [Related]
48. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
Müllertz S
Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
[TBL] [Abstract][Full Text] [Related]
49. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
Aoki N; Moroi M; Tachiya K
Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
[TBL] [Abstract][Full Text] [Related]
50. Enhanced fibrinolysis by proteolysed coagulation factor Xa.
Talbot K; Meixner SC; Pryzdial EL
Biochim Biophys Acta; 2010 Apr; 1804(4):723-30. PubMed ID: 19931652
[TBL] [Abstract][Full Text] [Related]
51. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
52. Plasma fibronectin enhances fibrinolytic system in vitro.
Gilboa N; Kaplan JE
Thromb Haemost; 1985 Oct; 54(3):639-44. PubMed ID: 2935966
[TBL] [Abstract][Full Text] [Related]
53. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
Jones AJ; Meunier AM
Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
[TBL] [Abstract][Full Text] [Related]
54. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
55. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
[TBL] [Abstract][Full Text] [Related]
56. Fibrin suspension as a substrate fop plasmin: determination and kinetics.
Kanai S; Okamoto H; Tamaura Y; Yamazaki S; Inada Y
Thromb Haemost; 1979 Dec; 42(4):1153-8. PubMed ID: 161668
[TBL] [Abstract][Full Text] [Related]
57. Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer.
Choi KS; Fitzpatrick SL; Filipenko NR; Fogg DK; Kassam G; Magliocco AM; Waisman DM
J Biol Chem; 2001 Jul; 276(27):25212-21. PubMed ID: 11319229
[TBL] [Abstract][Full Text] [Related]
58. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin.
Higgins DL; Vehar GA
Biochemistry; 1987 Dec; 26(24):7786-91. PubMed ID: 2962641
[TBL] [Abstract][Full Text] [Related]
59. Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis.
Ge M; Tang G; Ryan TJ; Malik AB
J Clin Invest; 1992 Dec; 90(6):2508-16. PubMed ID: 1281836
[TBL] [Abstract][Full Text] [Related]
60. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
